Virometix closes extension financing round28.11.2014 12:37
Virometix announced that it has closed an extension to its recent financing round. The start-up will use the proceeds to further speed up the development of its vaccine candidates for infectious and viral diseases.
The company from Schlieren announced the first closing of its first financing round in May. Furthermore the company announced the appointment of Ralf Rosenow, attorney-at-law and partner of the law firm Blum&Grob, Attorneys at Law Ltd., to its Board of Directors. Mr. Rosenow has served as a legal counsel to the company since 2012. He has longstanding experience in contract law, particularly within the biotech, pharmaceutical and medtech industry, and further advises companies in financings and capital market transactions, including IPOs.
Virometix AG is a privately held biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infectious and chronic human diseases.
In an increasingly global world there is a considerable medical need for vaccines to combat infectious as well as a number of chronic human diseases. Fast growing demands, health threats from newly arising complex viral and bacterial pathogens and increasingly stringent requirements for stability, safety and tolerability require new approaches to tackling current and future challenges.
Rational molecular design, chemical synthesis and Virometix' proprietary Synthetic Virus-Like Particle platform technology allow for the rapid production and optimization of vaccine candidates with superior properties in terms of safety, efficacy and stability.
Virometix is a spin-out company from the University of Zurich. Virometix AG was founded end of 2009 and moved to new premises in Schlieren this summer.